Global Mendelian disorder testing Market - Overview
The Mendelian disorder is genetic disorder in humans which arises due to mutation in a single gene. Mendelian disorder can be predicted with the help of a genograms. Hemophilia, thalassemia, color blindness, cystic fibrosis, sickle cell anemia, and phenylketonuria are the most common mendelian disorders. Mendelian disorder is of four types autosomal dominant, autosomal recessive, sex-linked dominant and sex-linked recessive. Genetic testing allows diagnosis of inherited diseases, it determines the changes in chromosomes, genes, proteins and metabolites. Some of the available genetic tests are: cell free foetal DNA testing, new-born screening, prenatal diagnosis, carrier testing, preimplantation genetic diagnosis, predictive and presymptomatic testing.
Request Sample Copy:
https://www.marketresearchfuture.com/sample_request/5500
Globally mendelian disorders testing market is estimated to grow at a rate of 6.5% during the forecast period.
The market is going to continue with the same trends of growth during the forecast period 2017-2023. According to U.S. Department of Health and Human Services, there are 70,000 to 80000 Americans affected by sickle cell disease, an inherited blood disorder. Thousands of new-borns are detected with beta thalassemia each year. Beta thalassemia is normally affects people from Central Asia, the Middle East, India, Southeast Asia, Mediterranean countries, and North Africa. Cystic fibrosis, a genetic disease occurs in 1 in 2,500 to 3,500 US new-borns.
Global Mendelian disorder testing Market - Competitive Analysis
There are many players of the market, but the existing players are strengthening their position in the industry by innovating technically advanced products. With well-established market, major companies like Abbott laboratories, ELITech Biomedical Systems, Thermo Fisher Scientific, Myriad Genetics Inc. and others acquire maximum market share.
Founded in 1900, Abbott laboratories discovers, develops, and markets a series of healthcare products. The company's Diagnostic Products include diagnostic systems and tests manufactured, marketed, and sold worldwide. In August 2016, Abbott introduced Alinity, a next-generation system used to carry out immunoassay, clinical chemistry, hematology, blood and plasma screening and molecular diagnostics. With the launch of Alinity portfolio, the company will be able to offer more efficiency and flexibility to doctors and scientists and help them improve decision-making and patient care.
Some of key the players in the global mendelian disorders testing market are Bio-Rad Laboratories, Inc. (U.S.),Transgenomic Inc. (U.S.), ELITechGroup (France), Quest Diagnostics (U.S.), AutoGenomics (U.S.), Abbott Laboratories (U.S.),PerkinElmer Inc. (U.S.), Celera Group (U.S.), Roche Diagnostics (Switzerland), Applied Biosystems Inc. (U.S.), Thermo Fisher Scientific and others.
Browse Complete Report with TOC at
https://www.marketresearchfuture.com/reports/mendelian-disorders-testing-market-5500
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Email: [email protected]
